Drugs / Milademetan
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03647202 | Aug → Sep 2018 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 0 | NCT03614455 | Jul → Oct 2018 | — | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 16 trials | ||||||
| Phase 1 | NCT05758818 | Apr → Jun 2023 | — | Rain Oncology Inc | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03552029 | Dec 2018 → Apr 2021 | acute myeloid leukemia | Daiichi Sankyo | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03671564 | Aug 2018 → Sep 2019 | acute myeloid leukemia | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1 | NCT02579824 | Aug 2016 → Nov 2019 | plasma cell myeloma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT02319369 | Nov 2014 → Aug 2020 | acute myeloid leukemia, myelodysplastic syndrome | Daiichi Sankyo | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT01877382 | Jul 2013 → Oct 2020 | lymphoma | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06090318 | May 2023 | gastric cancer, head and neck squamous cell carcinoma, melanoma, mesothelioma +4 | Rain Oncology Inc | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT03634228 | Dec 2018 → Apr 2022 | acute myeloid leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05932667 | Oct → Nov 2023 | breast cancer | Institut Curie | Terminated | No outcome recorded Stop: Business |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Milademetan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05932667 ↗ |
| Known as | DS3032b | “A Phase I study of Milademetan (DS3032b) in combination with low dose cytarabine” PMID 37386016 ↗ Jun 2023 |
| Known as | Milademetan Tosylate | “Drug: Milademetan Tosylate” NCT03634228 ↗ |
| Known as | RAIN-32 | “Milademetan (RAIN-32): 260 mg orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.” NCT06090318 ↗ |
| Action | Inhibit | “a small-molecule murine double minute-2 (MDM2) inhibitor” PMID 36669146 ↗ Jan 2023 |
| Modality | Small molecule | “a small-molecule murine double minute-2 (MDM2) inhibitor” PMID 36669146 ↗ Jan 2023 |
| Route | Oral | “Milademetan will be administered as a single oral capsule” NCT01877382 ↗ |
| Target | MDM2 | “a small-molecule murine double minute-2 (MDM2) inhibitor” PMID 36669146 ↗ Jan 2023 |